Literature DB >> 11973141

Tsg101: HIV-1's ticket to ride.

Carol A Carter1.   

Abstract

Recent studies implicate the vacuolar protein-sorting pathway in the transport of the retroviral structural precursor (Gag) protein to its budding site on the plasma membrane of infected cells. This exploitation of the cellular endocytic trafficking machinery to release viral particles could lead to the identification of virus-specific modulators and provide opportunities to design new targeted anti-viral agents.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11973141     DOI： 10.1016/s0966-842x(02)02350-8

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN： 0966-842X            Impact factor:   17.079


  26 in total

1.  The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies.

Authors:  Mar Perez; Rebecca C Craven; Juan C de la Torre
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-16       Impact factor: 11.205

2.  Overlapping motifs (PTAP and PPEY) within the Ebola virus VP40 protein function independently as late budding domains: involvement of host proteins TSG101 and VPS-4.

Authors:  Jillian M Licata; Martha Simpson-Holley; Nathan T Wright; Ziying Han; Jason Paragas; Ronald N Harty
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

3.  Functional surfaces of the human immunodeficiency virus type 1 capsid protein.

Authors:  Uta K von Schwedler; Kirsten M Stray; Jennifer E Garrus; Wesley I Sundquist
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

4.  Viral and host proteins that modulate filovirus budding.

Authors:  Yuliang Liu; Ronald N Harty
Journal:  Future Virol       Date:  2010-07-01       Impact factor: 1.831

5.  The cellular HIV-1 Rev cofactor hRIP is required for viral replication.

Authors:  Zhong Yu; Nuria Sánchez-Velar; Irina E Catrina; Ellen L W Kittler; Enyeneama B Udofia; Maria L Zapp
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-04       Impact factor: 11.205

6.  Budding of retroviruses utilizing divergent L domains requires nucleocapsid.

Authors:  Nana F Bello; Vincent Dussupt; Paola Sette; Victoria Rudd; Kunio Nagashima; Frederic Bibollet-Ruche; Chaoping Chen; Ronald C Montelaro; Beatrice H Hahn; Fadila Bouamr
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

7.  FGI-104: a broad-spectrum small molecule inhibitor of viral infection.

Authors:  Michael S Kinch; Abdul S Yunus; Calli Lear; Hanwen Mao; Hanson Chen; Zena Fesseha; Guangxiang Luo; Eric A Nelson; Limin Li; Zhuhui Huang; Michael Murray; William Y Ellis; Lisa Hensley; Jane Christopher-Hennings; Gene G Olinger; Michael Goldblatt
Journal:  Am J Transl Res       Date:  2009-01-05       Impact factor: 4.060

8.  Class II transactivator (CIITA) enhances cytoplasmic processing of HIV-1 Pr55Gag.

Authors:  Kristen A Porter; Lauren N Kelley; Annette George; Jonathan A Harton; Karen M Duus
Journal:  PLoS One       Date:  2010-06-24       Impact factor: 3.240

9.  Tsg101 control of human immunodeficiency virus type 1 Gag trafficking and release.

Authors:  A Goff; L S Ehrlich; S N Cohen; C A Carter
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  The nucleocapsid region of HIV-1 Gag cooperates with the PTAP and LYPXnL late domains to recruit the cellular machinery necessary for viral budding.

Authors:  Vincent Dussupt; Melodi P Javid; Georges Abou-Jaoudé; Joshua A Jadwin; Jason de La Cruz; Kunio Nagashima; Fadila Bouamr
Journal:  PLoS Pathog       Date:  2009-03-13       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.